<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Icahn Offered $23 Billion for Biogen Idec—Elan Won’t Block Sale</title>
	<atom:link href="http://www.xconomy.com/boston/2007/10/15/ichan-offered-23-billion-for-biogen-idec-elan-wont-block-sale/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/boston/2007/10/15/ichan-offered-23-billion-for-biogen-idec-elan-wont-block-sale/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 11 Feb 2012 03:54:18 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
	<item>
		<title>By: Robert Buderi</title>
		<link>http://www.xconomy.com/boston/2007/10/15/ichan-offered-23-billion-for-biogen-idec-elan-wont-block-sale/comment-page-1/#comment-1890</link>
		<dc:creator>Robert Buderi</dc:creator>
		<pubDate>Mon, 15 Oct 2007 15:39:33 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/2007/10/15/ichan-offered-23-billion-for-biogen-idec-elan-wont-block-sale/#comment-1890</guid>
		<description>Hi Jim--Thanks for the note. As we reported briefly in &lt;a href=&quot;http://www.xconomy.com/2007/08/27/carl-icahn-biogen-marriage-broker/2/&quot; rel=&quot;nofollow&quot;&gt;this article about Icahn&lt;/a&gt;, Pfizer has received attention as the most likely Big Pharma suitor, but we have nothing new on this. My guess is that given the problems with Pfizer&#039;s pipeline, they would have to give this a serious look.</description>
		<content:encoded><![CDATA[<p>Hi Jim–Thanks for the note. As we reported briefly in <a href="http://www.xconomy.com/2007/08/27/carl-icahn-biogen-marriage-broker/2/" rel="nofollow">this article about Icahn</a>, Pfizer has received attention as the most likely Big Pharma suitor, but we have nothing new on this. My guess is that given the problems with Pfizer’s pipeline, they would have to give this a serious look.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Jim</title>
		<link>http://www.xconomy.com/boston/2007/10/15/ichan-offered-23-billion-for-biogen-idec-elan-wont-block-sale/comment-page-1/#comment-1889</link>
		<dc:creator>Jim</dc:creator>
		<pubDate>Mon, 15 Oct 2007 15:20:01 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/2007/10/15/ichan-offered-23-billion-for-biogen-idec-elan-wont-block-sale/#comment-1889</guid>
		<description>Pfizer seems like it could be a worthy opponent of Icahn for Biogen based on some of these connections from NewsVisual: http://www.newsvisual.com/newsvisual/2007/10/biogen-and-pfiz.html

Thoughts as to whether Pfizer actually stands a chance in becoming Icahn&#039;s &#039;poison pill&#039;?</description>
		<content:encoded><![CDATA[<p>Pfizer seems like it could be a worthy opponent of Icahn for Biogen based on some of these connections from NewsVisual: <a href="http://www.newsvisual.com/newsvisual/2007/10/biogen-and-pfiz.html" rel="nofollow">http://www.newsvisual.com/newsvisual/2007/10/biogen-and-pfiz.html</a></p>
<p>Thoughts as to whether Pfizer actually stands a chance in becoming Icahn’s ‘poison pill’?</p>
]]></content:encoded>
	</item>
</channel>
</rss>

